A newly evolved variant of the norovirus GII.17 genotype is driving a surge in gastroenteritis outbreaks across Europe and the Americas, according to research published this week in Nature Communications. The virus, historically less prevalent than other strains, has demonstrated a concerning ability to adapt and evade immunity, prompting international investigation led by the U.S. Food and Drug Administration and the Robert Koch Institute of Germany.Scientists warn that understanding the virus’s rapid evolution is now critical for public health officials to prepare for and mitigate potential epidemics.
An international team of scientists led by the U.S. Food and Drug Administration (FDA) and the Robert Koch Institute of Germany has identified a new variant of norovirus GII.17 driving a global increase in gastroenteritis outbreaks since 2023. The study, recently published in the journal Nature Communications, reveals this specific genotype has evolved to significantly enhance its ability to infect humans. Norovirus is a highly contagious virus that causes vomiting and diarrhea, and understanding its evolution is crucial for public health preparedness.
Historically not among the top ten most prevalent strains, the GII.17 genotype began spreading from several Asian countries between 2013 and 2016, giving rise to variants C and D. While cases later decreased and GII.4 regained global dominance, a significant resurgence of infections caused by this specific norovirus variant has been reported in numerous European and American countries since 2023.
“The study shows that the new variant of norovirus GII.17 has undergone a dynamic evolutionary process, adapting to infect humans more effectively,” explained María Dolores Fernández-García, head of Viral Gastroenteritis at the National Center for Microbiology of the ISCIII and a collaborator on this research. She highlighted that the new variant exhibits distinct genetic modifications, particularly in the VP1 protein of the viral capsid.
Genetic Changes Boost Infection Potential
The mutations detected in this new variant have markedly improved the virus’s ability to bind to sugar molecules that facilitate infection. These changes have also altered the pathogen’s antigenic properties, allowing it to evade recognition by the immune system and promote infection development.
Comparative analyses demonstrate that this version of GII.17 exhibits a greater capacity and versatility for cellular attachment than previous Asian variants C and D. This adaptation has broadened the range of individuals susceptible to infection, contributing to its rapid spread across Europe and America over the past two years.
Researchers also found a significant observation: some of the most relevant adaptive mutations were already being selected at the individual level before spreading to the general population. “The story of the GII.17 variant is an example of how viruses evolve to find new opportunities for infection; only by understanding these mechanisms can we anticipate and prevent them from becoming large epidemics,” Fernández-García noted.
The Importance of Global Genomic Surveillance
During the investigation, scientists analyzed over 1,400 viral genomes, both recent and archived in international databases. The work included complete genomes of norovirus GII.17 obtained in Spain through molecular characterization of outbreaks coordinated by the National Center for Microbiology.
The researchers thoroughly examined the global patterns of viral diversification at the genomic level, as well as the specific mutations detected in 511 viruses over a decade of surveillance in Germany. The study also delved into intra-host viral diversity and the adaptive processes that led to the predominance of GII.17.
Fernández-García emphasized that this research underscores the critical importance of international collaboration and genomic surveillance for understanding viral evolution and adaptation – aspects fundamental to effectively protecting public health. She added that understanding how small mutations in the VP1 protein affect the virus’s ability to infect cells and evade natural immunity could contribute to the development of more effective vaccines and the anticipation of future variants. The findings highlight the need for continued monitoring and research to stay ahead of evolving viral threats.
